Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis

Cytokine and Growth Factor Reviews

Volumn 23, Issue 1-2, 2012, Pages 25-35

  Huang, Chen ^a,b   Xie, Keping ^b  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Metastasis; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETULIC ACID; BEVACIZUMAB; CELECOXIB; CUCURBITACIN B; CUCURBITACIN E; CUCURBITACIN I; FLLL 31; FLLL 32; GLUCOSE PENTAGALLATE; INTERLEUKIN 12; IS 3 295; JSI 124; MITHRAMYCIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOPEPTIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; TERPENOID; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; DRUG TARGETING; GENE ACTIVATION; GENE MUTATION; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYELOMA; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS SURGERY; PLASMACYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR VASCULARIZATION;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTEIN BINDING; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 84862798695     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.01.003     Document Type: Review

References (140)

1. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
3. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
4. Stathis A., Moore M.J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010, 7:163-172.
5. Neoptolemos J.P., Cunningham D., Friess H., Bassi C., Stocken D.D., Tait D.M., et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003, 14:675-692.
6. Yokoyama Y., Nimura Y., Nagino M. Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies. Surg Today 2009, 39:466-475.
7. Suske G. The Sp-family of transcription factors. Gene 1999, 238:291-300.
8. Li L., He S., Sun J.M., Davie J.R. Gene regulation by Sp1 and Sp3. Biochem Cell Biol 2004, 82:460-471.
9. Safe S., Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005, 41:2438-2448.
10. Shi Q., Le X., Abbruzzese J.L., Peng Z., Qian C.N., Tang H., et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001, 61:4143-4154.
11. Wang L., Wei D., Huang S., Peng Z., Le X., Wu T.T., et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003, 9:6371-6380.
12. Lou Z., O'Reilly S., Liang H., Maher V.M., Sleight S.D., McCormick J.J. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005, 65:1007-1017.
13. Kong L.M., Liao C.G., Fei F., Guo X., Xing J.L., Chen Z.N. Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer. Cancer Sci 2010, 101:1463-1470.
14. Lu S., Archer M.C. Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells. Int J Cancer 2010, 126:416-425.
15. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
16. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
17. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
18. Haura E.B., Turkson J., Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005, 2:315-324.
19. Frank D.A., Mahajan S., Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 1997, 100:3140-3148.
20. Ding B.B., Yu J.J., Yu R.Y., Mendez L.M., Shaknovich R., Zhang Y., et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111:1515-1523.
21. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002, 62:6659-6666.
22. Diaz N., Minton S., Cox C., Bowman T., Gritsko T., Garcia R., et al. Activation of Stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006, 12:20-28.
23. Scholz A., Heinze S., Detjen K.M., Peters M., Welzel M., Hauff P., et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 2003, 125:891-905.
24. Hruban R.H., Goggins M., Parsons J., Kern S.E. Progression model for pancreatic cancer. Clin Cancer Res 2000, 6:2969-2972.
25. Brugge W.R., Lauwers G.Y., Sahani D., Fernandez-del Castillo C., Warshaw A.L. Cystic neoplasms of the pancreas. N Engl J Med 2004, 351:1218-1226.
26. Maitra A., Fukushima N., Takaori K., Hruban R.H. Precursors to invasive pancreatic cancer. Adv Anat Pathol 2005, 12:81-91.
27. Xie K., Wei D., Huang S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev 2006, 17:147-156.
28. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
29. Feldmann G., Beaty R., Hruban R.H., Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007, 14:224-232.
30. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
31. Nebert D.W. Transcription factors and cancer: an overview. Toxicology 2002, 181-182:131-141.
32. Darnell J.E. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002, 2:740-749.
33. Kim R., Tanabe K., Emi M., Uchida Y., Inoue H., Toge T. Inducing cancer cell death by targeting transcription factors. Anticancer Drugs 2003, 14:3-11.
34. Redell M.S., Tweardy D.J. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005, 11:2873-2887.
35. Yao J.C., Wang L., Wei D., Gong W., Hassan M., Wu T.T., et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004, 10:4109-4117.
36. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
37. Ribatti D., Vacca A., Presta M. The discovery of angiogenic factors: a historical review. Gen Pharmacol 2000, 35:227-231.
38. Wang L., Guan X., Gong W., Yao J., Peng Z., Wei D., et al. Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis 2005, 22:205-213.
39. Wang L., Guan X., Zhang J., Jia Z., Wei D., Li Q., et al. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol 2008, 33:161-167.
40. Wei D., Wang L., He Y., Xiong H.Q., Abbruzzese J.L., Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004, 64:2030-2038.
41. Abdelrahim M., Smith R., Burghardt R., Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004, 64:6740-6749.
42. Higgins K.J., Abdelrahim M., Liu S., Yoon K., Safe S. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 2006, 345:292-301.
43. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
44. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005, 17:548-558.
45. Jungert K., Buck A., von W.G., Adler G., Konig A., Buchholz M., et al. Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 2007, 67:1563-1570.
46. Stetler-Stevenson W.G., Aznavoorian S., Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993, 9:541-573.
47. Nguyen T.H. Mechanisms of metastasis. Clin Dermatol 2004, 22:209-216.
48. Harvey S.R., Hurd T.C., Markus G., Martinick M.I., Penetrante R.M., Tan D., et al. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 2003, 9:4935-4943.
49. Tan X., Egami H., Nozawa F., Abe M., Baba H. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells. Int J Oncol 2006, 28:369-374.
50. Buchler P., Reber H.A., Tomlinson J.S., Hankinson O., Kallifatidis G., Friess H., et al. Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia 2009, 11:196-206.
51. Zannetti A., Del V.S., Carriero M.V., Fonti R., Franco P., Botti G., et al. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000, 60:1546-1551.
52. Zannetti A., Del V.S., Romanelli A., Scala S., Saviano M., Cali' G., et al. Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells. Biochem Pharmacol 2005, 70:1277-1287.
53. Jiang N.Y., Woda B.A., Banner B.F., Whalen G.F., Dresser K.A., Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17:1648-1652.
54. Abdelrahim M., Baker C.H., Abbruzzese J.L., Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006, 98:855-868.
55. Yuan P., Wang L., Wei D., Zhang J., Jia Z., Li Q., et al. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 2007, 110:2682-2690.
56. Abdelrahim M., Baker C.H., Abbruzzese J.L., Sheikh-Hamad D., Liu S., Cho S.D., et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007, 67:3286-3294.
57. Koutsodontis G., Kardassis D. Inhibition of p53-mediated transcriptional responses by mithramycin A. Oncogene 2004, 23:9190-9200.
58. Jia Z., Gao Y., Wang L., Li Q., Zhang J., Le X., et al. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res 2010, 70:1111-1119.
59. Chintharlapalli S., Papineni S., Ramaiah S.K., Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007, 67:2816-2823.
60. Jia Z., Zhang J., Wei D., Wang L., Yuan P., Le X., et al. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res 2007, 67:4878-4885.
61. Gao Y., Jia Z., Kong X., Li Q., Chang D.Z., Wei D., et al. Combining betulinic acid and mithramycin A effectively suppresses pancreatic cancer by inhibiting proliferation, invasion and angiogenesis. Cancer Res 2011, 71:5182-5193.
62. Buettner R., Mora L., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8:945-954.
63. Toyonaga T., Nakano K., Nagano M., Zhao G., Yamaguchi K., Kuroki S., et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 2003, 201:107-116.
64. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003, 22:319-329.
65. Jing N., Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16:601-607.
66. Ivanov V.N., Bhoumik A., Krasilnikov M., Raz R., Owen-Schaub L.B., Levy D., et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 2001, 7:517-528.
67. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
68. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
69. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1expression. J Clin Invest 2001, 107:351-362.
70. Huang S., Sinicrope F.A. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 2010, 9:742-750.
71. Aoki Y., Feldman G.M., Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101:1535-1542.
72. Glienke W., Maute L., Wicht J., Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest 2010, 28:166-171.
73. Martino A., Holmes J.H., Lord J.D., Moon J.J., Nelson B.H. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J Immunol 2001, 166:1723-1729.
74. Kijima T., Niwa H., Steinman R.A., Drenning S.D., Gooding W.E., Wentzel A.L., et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002, 13:355-362.
75. Masuda M., Suzui M., Yasumatu R., Nakashima T., Kuratomi Y., Azuma K., et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002, 62:3351-3355.
76. Sinibaldi D., Wharton W., Turkson J., Bowman T., Pledger W.J., Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000, 19:5419-5427.
77. Glienke W., Hausmann E., Bergmann L. Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell lines. Tumour Biol 2011, 32:493-500.
78. Glienke W., Hausmann E., Bergmann L. Targeting STAT3 signaling in pancreatic cancer promotes antiapoptotic gene expression. Pancreas 2011, 40:323-324.
79. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
80. Volpert O.V., Dameron K.M., Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997, 14:1495-1502.
81. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
82. Grunstein J., Roberts W.G., Mathieu-Costello O., Hanahan D., Johnson R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999, 59:1592-1598.
83. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
84. Xu Q., Briggs J., Park S., Niu G., Kortylewski M., Zhang S., et al. Targeting Stat3 blocks both HIF-1and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24:5552-5560.
85. Bartoli M., Platt D., Lemtalsi T., Gu X., Brooks S.E., Marrero M.B., et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J 2003, 17:1562-1564.
86. Yahata Y., Shirakata Y., Tokumaru S., Yamasaki K., Sayama K., Hanakawa Y., et al. Nuclear translocation of phosphorylated STAT3 is essential for VEGF-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem 2003, 278:40026-40031.
87. Xie T.X., Huang F.J., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., et al. Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res 2006, 66:3188-3196.
88. Huang C., Jiang T., Zhu L., Liu J., Cao J., Huang K.J., et al. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. Int J Oncol 2011, 38:1637-1644.
89. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
90. Chang K.C., Wu M.H., Jones D., Chen F.F., Tseng Y.L. Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour. J Pathol 2006, 210:224-233.
91. Kusaba T., Nakayama T., Yamazumi K., Yakata Y., Yoshizaki A., Nagayasu T., et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005, 58:833-838.
92. Suiqing C., Min Z., Lirong C. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol 2005, 32:354-360.
93. Horiguchi A., Oya M., Shimada T., Uchida A., Marumo K., Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 2002, 168:762-765.
94. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23:3550-3560.
95. Hsieh F.C., Cheng G., Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 2005, 335:292-299.
96. Itoh M., Murata T., Suzuki T., Shindoh M., Nakajima K., Imai K., et al. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2006, 25:1195-1204.
97. Silver D.L., Naora H., Liu J., Cheng W., Montell D.J. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004, 64:3550-3558.
98. Huang C., Cao J., Huang K.J., Zhang F., Jiang T., Zhu L., et al. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci 2006, 97:1417-1423.
99. Qiu Z., Huang C., Sun J., Qiu W., Zhang J., Li H., et al. RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci 2007, 98:1099-1106.
100. Zhao S., Venkatasubbarao K., Lazor J.W., Sperry J., Jin C., Cao L., et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 2008, 68:4221-4228.
101. Huang C., Yang G., Jiang T., Zhu G., Li H., Qiu Z. The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro. Neoplasma 2011, 58:396-405.
102. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003, 63:1270-1279.
103. Gao L., Zhang L., Hu J., Li F., Shao Y., Zhao D., et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005, 11:6333-6341.
104. Song H., Wang R., Wang S., Lin J. A low-molecular weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005, 102:4700-4705.
105. Leong P.L., Andrews G.A., Johnson D.E., Dyer K.F., Xi S., Mai J.C., et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003, 100:4138-4143.
106. Turkson J., Ryan D., Kim J.S., Zhang Y., Chen Z., Haura E., et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001, 276:45443-45455.
107. Catlett-Falcone R., Dalton W.S., Joce R. STAT proteins as novel targets for cancer therapy. Curr Opin Oncol 1999, 11:490-496.
108. Burdelya L., Catlett-Falcone R., Levitzki A., Cheng F., Mora L.B., Sotomayor E., et al. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther 2002, 1:893-899.
109. Thoennissen N.H., Iwanski G.B., Doan N.B., Okamoto R., Lin P., Abbassi S., et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009, 69:5876-5884.
110. Zhang M., Sun C., Shan X., Yang X., Li-Ling J., Deng Y. Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling. Pancreas 2010, 39:923-929.
111. Sun C., Zhang M., Shan X., Zhou X., Yang J., Wang Y., et al. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol 2010, 136:603-610.
112. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
113. Hammond S.M., Caudy A.A., Hannon G.J. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001, 2:110-119.
114. Elbashir S.M., Lendeckel W., Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001, 15:188-200.
115. Lee S.O., Lou W., Qureshi K.M., Mehraein-Ghomi F., Trump D.L., Gao A.C. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 2004, 60:303-309.
116. Huang C., Yang G., Jiang T., Cao J., Huang K.J., Qiu Z.J. Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth. World J Gastroenterol 2011, 17:2992-3001.
117. Brummelkamp T.R., Bernards R., Agami R. Stabl esuppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2:243-247.
118. Qin X.F., An D.S., Chen I.S., Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003, 100:183-188.
119. Ling X., Arlinghaus R.B. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005, 65:2532-2536.
120. Yang G., Huang C., Cao J., Huang K.J., Jiang T., Qiu Z.J. Lentivirus-mediated shRNA interference targeting STAT3 inhibits human pancreatic cancer cell invasion. World J Gastroenterol 2009, 15:3757-3766.
121. Turkson J., Zhang S., Mora L.B., Burns A., Sebti S., Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005, 280:32979-32988.
122. Kim B.H., Yin C.H., Guo Q., Bach E.A., Lee H., Sandoval C., et al. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells. Mol Cancer Ther 2008, 7:2672-2680.
123. Chen C.L., Cen L., Kohout J., Hutzen B., Chan C., Hsieh F.C., et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer 2008, 7:78.
124. Fuh B., Sobo M., Cen L., Josiah D., Hutzen B., Cisek K., et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer 2009, 100:106-112.
125. Lin L., Hutzen B., Zuo M., Ball S., Deangelis S., Foust E., et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010, 70:2445-2454.
126. Grivennikov S.I., Karin M. Dangerous liaisons: Stat3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010, 21:11-19.
127. Tan N.Y., Khachigian L.M. Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 2009, 29:2483-2488.
128. Gibadulinova A., Oveckova I., Parkkila S., Pastorekova S., Pastorek J. Key promoter elements involved in transcriptional activation of the cancer-related gene coding for S100P calcium-binding protein. Oncol Rep 2008, 20:391-396.
129. Cantwell C.A., Sterneck E., Johnson P.F. Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol 1998, 18:2108-2117.
130. Mangan J.K., Rane S.G., Kang A.D., Amanullah A., Wong B.C., Reddy E.P. Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood 2004, 103:4093-4101.
131. Look D.C., Pelletier M.R., Tidwell R.M., Roswit W.T., Holtzman M.J. Stat1 depends on transcriptional synergy with Sp1. J Biol Chem 1995, 270:30264-30267.
132. Canaff L., Zhou X., Hendy G.N. The proinflammatory cytokine, interleukin-6, up-regulates calcium-sensing receptor gene transcription via Stat1/3 and Sp1/3. J Biol Chem 2008, 283:13586-13600.
133. Gray M.J., Zhang J., Ellis L.M., Semenza G.L., Evans D.B., Watowich S.S., et al. HIF-1a, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24:3110-3120.
134. Ehlting C., Haussinger D., Bode J.G. Sp3 is involved in the regulation of SOCS3 gene expression. Biochem J 2005, 387:737-745.
135. Letourneur M., Valentino L., Travagli-Gross J., Bertoglio J., Pierre J. Sp2 regulates interferon-gamma-mediated socs1 gene expression. Mol Immunol 2009, 46:2151-2160.
136. Barclay J.L., Anderson S.T., Waters M.J., Curlewis J.D. SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer 2009, 124:1756-1766.
137. Shibata F., Baird A., Florkiewicz R.Z. Functional characterization of the human basic fibroblast growth factor gene promoter. Growth Factors 1991, 4:277-287.
138. Zhang J., Li L., Kim S.H., Hagerman A.E., Lu J. Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucose. Pharm Res 2009, 26:2066-2080.
139. Kunigal S., Lakka S.S., Gondi C.S., Estes N., Rao J.S. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007, 121:2307-2316.
140. Seth S., Matsui Y., Fosnaugh K., Liu Y., Vaish N., Adami R., et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther 2011, 19:928-935.